XM does not provide services to residents of the United States of America.
L
L

Lonza


News

Swiss trade surplus at CHF 8.063 bln in October

TABLE-Swiss trade surplus at CHF 8.063 bln in October November 19 (Reuters) - Switzerland ran a merchandise trade surplus of 8 .063 billion Swiss francs in October, the Federal Customs Office said on Tuesday. KEY FIGURES (millions of Swiss francs) October 2024 September 2024 Imports 19.681 17.620 Exports 27.745 22.562 Balance 8.063 4.942 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Lonza To Expand Bioconjugation In Visp With Two Additional Manufacturing Suites

BRIEF-Lonza To Expand Bioconjugation In Visp With Two Additional Manufacturing Suites Nov 12 (Reuters) - LONZA GROUP AG LONN.S : TO EXPAND BIOCONJUGATION IN VISP (CH) WITH TWO ADDITIONAL MANUFACTURING SUITES NEW CAPACITY WILL GENERATE APPROXIMATELY 200 NEW JOBS AND IS EXPECTED TO BE OPERATIONAL FROM 2028 Source text: ID:nEQ85bdK2a Further company c
L

Lonza Group AG Synaffix Collaborates With Bighat Biosciences On Development Of Machine Learning-Designed Adc

BRIEF-Lonza Group AG Synaffix Collaborates With Bighat Biosciences On Development Of Machine Learning-Designed Adc Nov 4 (Reuters) - Lonza Group AG LONN.S : LONZA GROUP AG: SYNAFFIX COLLABORATES WITH BIGHAT BIOSCIENCES ON DEVELOPMENT OF MACHINE LEARNING-DESIGNED ADC Source text: ID:nPreZQpDla Further company coverage: LONN.S ( Reuters.Briefs@thomso
L

Lonza Group Confirms Full Year Outlook

BRIEF-Lonza Group Confirms Full Year Outlook Oct 24 (Reuters) - LONZA GROUP AG LONN.S : OUTLOOK 2024 CONFIRMED: FLAT YEAR-ON-YEAR SALES IN CER AND A CORE EBITDA MARGIN OF HIGH 20S DEMAND REMAINS SOFT IN CAPSULES & HEALTH INGREDIENTS AND BIOSCIENCE BUSINESSES Q3 PERFORMANCE IN LINE Further company coverage: LONN.S (Gdansk Newsroom)
L

Lonza Extends Collaboration With Major Pharmaceutical Partner For Integrated Commercial Supply Of Antibody-Drug Conjugates

BRIEF-Lonza Extends Collaboration With Major Pharmaceutical Partner For Integrated Commercial Supply Of Antibody-Drug Conjugates Oct 22 (Reuters) - LONZA GROUP AG LONN.S : EXTENDS COLLABORATION WITH MAJOR PHARMACEUTICAL PARTNER FOR INTEGRATED COMMERCIAL SUPPLY OF ANTIBODY-DRUG CONJUGATES EXTENSION OF LONG-TERM COLLABORATION INCLUDES CONSTRUCTION OF
L

Swiss trade surplus at CHF 4.946 bln in September

TABLE-Swiss trade surplus at CHF 4.946 bln in September Oct 17 (Reuters) - Switzerland ran a merchandise trade surplus of 4.946 billion Swiss francs in September, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) September 2024 August 2024 Imports 17.579 15.905 Exports 22.526 20.649 Balance 4.946 4.744 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Top of the Street: ING, Lonza, Repsol

BUZZ-Top of the Street: ING, Lonza, Repsol A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts ING INGA.AS to "hold" from "buy" saying it expects less support from the Dutch lender's large but relatively short replicating portfolio going forward; it sees falling revenues next year while cost inflation will likely remain elevated, resulting in efficiency deterioration in 2025 ** Exane BNP Paribas downgrades Repsol REP.MC to "neutral" from "
I
L
R

Lonza And Vertex Sign A Supply Agreement For Casgevy®

BRIEF-Lonza And Vertex Sign A Supply Agreement For Casgevy® Sept 24 (Reuters) - LONZA GROUP AG LONN.S : LONZA AND VERTEX SIGN A LONG-TERM COMMERCIAL SUPPLY AGREEMENT FOR CASGEVY® (EXAGAMGLOGENE AUTOTEMCEL) LONZA GROUP AG - TO MANUFACTURE WORLD'S FIRST CRISPR/CAS9 CELL THERAPY LONZA GROUP AG - GELEEN (NL) SITE IS NOW APPROVED BY FDA, EMA AND MHRA
L

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Stifel adjusts ratings on European pharma; downgrades Sartorius, Siegfried ahead of H2

BUZZ-Stifel adjusts ratings on European pharma; downgrades Sartorius, Siegfried ahead of H2 ** Stifel shares thoughts on European pharmaceutical companies heading into H2; downgrades Sartorius SATG.DE and Siegfried SFZN.S to "hold", citing concerns over growth catalysts and valuation alignment with recent strong performance ** The analyst flags the
L

Alstom, Siemens, Tesco

EUROPE RESEARCH ROUNDUP-Alstom, Siemens, Tesco Sept 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alstom, Siemens and Tesco, on Friday. HIGHLIGHTS * Alstom ALSO.PA : HSBC raises target price to EUR 26 from EUR 24 * Hexagon AB HEXAB.ST : HSBC cuts target price to SEK 110 from SEK 120 * Siemens AG SIEGN.DE : HSBC cuts target price to EUR 140 from EUR 150 * Tesco TSCO.L : Citigroup raises target price to 425p from 350p * Travis P
A
A
A
B
B
B
C
C
C
D
D
E
E
F
H
H
I
K
L
L
S
S
S
S
T
T
P
A
A
F
S
U

Swiss stocks - Factors to watch on September 13

Swiss stocks - Factors to watch on September 13 ZURICH/GDANSK, Sept 13 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Friday: A survey of Swiss banks has highlighted international sanctions imposed on other countries, such as against Russia over Ukraine, as the greatest geopolitical risk to their business. ANALYSTS' VIEWS ABB ABBN.S - HSBC RAISES TARGET PRICE TO CHF 45 FROM CHF 43 ALCON ALCC.S - HSBC CUTS TARGET PRICE TO CHF 89 FROM CHF 91 LONZA LONN.S - HSBC RAISE
A
L
S
S

Swiss stocks - Factors to watch on August 29

Swiss stocks - Factors to watch on August 29 ZURICH/GDANSK, Aug 29(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: Swiss court convicts two executives over $1.8 billion 1MDB fraud The Swiss Federal Criminal Court convicted on Wednesday two executives at an oil exploration company for embezzling more than $1.8 billion from Malaysia's state investment fund 1MDB.
L
S

Lonza Says Co Prices EUR 1.2 Bln Dual-Tranche Straight Bonds

BRIEF-Lonza Says Co Prices EUR 1.2 Bln Dual-Tranche Straight Bonds Aug 28 (Reuters) - Lonza Group AG LONN.S : LONZA PRICES EUR 1.2 BILLION DUAL-TRANCHE STRAIGHT BONDS LONZA GROUP - BONDS FOR LONZA FINANCE INTERNATIONAL HAVE MATURITY OF 6 AND 10 YEARS WITH COUPONS OF 3.25% AND 3.50% RESPECTIVELY Source text for Eikon: ID:nEQbznFm8a Further company c
L



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.